Ocuphire Pharma, Inc. Stock News

Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024 Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024

Ocuphire Pharma, Inc. (NASDAQ:OCUP ) Corporate Update Call December 5, 2023 10:00 AM ET Company Participants Dr. George Magrath - Chief Executive Officer Michael Wood - LifeSci Advisors Charlie Hoffma

Ocuphire Pharma, Inc. (OCUP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions co

Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023 Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023

After a rocky couple of years, there finally seems to be some light at the end of the tunnel for growth stocks. Interest rates have stabilized, and the economy is again showing signs of strength.

FARMINGTON HILLS, Mich., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-m

Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy

Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis

FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-m

Penny stocks have a horrible reputation for the most part and it's not necessarily undeserved. Too many times, charlatans hawk their junk securities, often in the over-the-counter market where regulat

PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.

While the adage that you get what you pay for generally rings true, you can sometimes cheat up this narrative with the best stocks to buy under $10. While you can't get much for a Hamilton these days,

While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappo

Ocuphire Pharma Inc OCUP was plunging over 22% at one point on Friday after the company announced it appointed Rick Rodgers to the role of interim CEO. An SEC filing, which stated former CEO Mina So

The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear